CN108523129A - A kind of auxiliary hyperglycemic composition and preparation method thereof - Google Patents
A kind of auxiliary hyperglycemic composition and preparation method thereof Download PDFInfo
- Publication number
- CN108523129A CN108523129A CN201810457024.8A CN201810457024A CN108523129A CN 108523129 A CN108523129 A CN 108523129A CN 201810457024 A CN201810457024 A CN 201810457024A CN 108523129 A CN108523129 A CN 108523129A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- auxiliary hyperglycemic
- dry
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003345 hyperglycaemic effect Effects 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims description 22
- 239000000284 extract Substances 0.000 claims abstract description 214
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 50
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 50
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 44
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 44
- 229940107666 astragalus root Drugs 0.000 claims abstract description 42
- 229940046374 chromium picolinate Drugs 0.000 claims abstract description 36
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000002994 raw material Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 239000000843 powder Substances 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 35
- 235000004879 dioscorea Nutrition 0.000 claims description 34
- 235000019441 ethanol Nutrition 0.000 claims description 31
- 239000002775 capsule Substances 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 22
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000006187 pill Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 244000241872 Lycium chinense Species 0.000 claims description 13
- 235000015468 Lycium chinense Nutrition 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 12
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 10
- 241000180649 Panax notoginseng Species 0.000 claims description 10
- 229940104640 chinese yam extract Drugs 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 9
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 9
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 9
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 2
- -1 Stilbene glucoside Chemical class 0.000 claims 2
- 229930182478 glucoside Natural products 0.000 claims 2
- 241000219780 Pueraria Species 0.000 claims 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims 1
- 150000008131 glucosides Chemical class 0.000 claims 1
- 239000000344 soap Substances 0.000 claims 1
- 235000021286 stilbenes Nutrition 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 53
- 239000008280 blood Substances 0.000 abstract description 50
- 230000000694 effects Effects 0.000 abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 15
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract description 5
- 230000002547 anomalous effect Effects 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 210000000952 spleen Anatomy 0.000 abstract description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 230000001502 supplementing effect Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 description 46
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 39
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 235000000346 sugar Nutrition 0.000 description 20
- 201000001421 hyperglycemia Diseases 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 229920001353 Dextrin Polymers 0.000 description 10
- 239000004375 Dextrin Substances 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 235000019425 dextrin Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000036541 health Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 239000009636 Huang Qi Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 239000011812 mixed powder Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000005498 polishing Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 3
- 241000219051 Fagopyrum Species 0.000 description 3
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- IOLDDENZPBFBHV-UHFFFAOYSA-N Kukoamine A Chemical compound C1=C(O)C(O)=CC=C1CCC(=O)NCCCNCCCCNCCCNC(=O)CCC1=CC=C(O)C(O)=C1 IOLDDENZPBFBHV-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- BWRVBFMWWHWLBW-UHFFFAOYSA-N Lyciumin B Chemical compound C12=CC=CC=C2N2C=C1CC(C(O)=O)NC(=O)C(CO)NC(=O)CNC(=O)C(C(C)C)NC(=O)C2NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCCN1C(=O)C1CCC(=O)N1 BWRVBFMWWHWLBW-UHFFFAOYSA-N 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 239000000864 hyperglycemic agent Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NAORGNSYBDQEPT-UHFFFAOYSA-N 3-phenylprop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=CC=C1.OC(=O)C=CC1=CC=CC=C1 NAORGNSYBDQEPT-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 240000004904 Amorphophallus paeoniifolius Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000008620 Cholesterol Assay Methods 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 206010060766 Heteroplasia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229930183024 Kukoamine Natural products 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- IPOLXDNCMOVXCP-YZVVJARPSA-N Lyciumin A Natural products O=C(N[C@H]1C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C(=O)O)Cc2c3c(n1c2)cccc3)[C@H](NC(=O)[C@H]1N(C(=O)[C@@H]2NC(=O)CC2)CCC1)Cc1ccc(O)cc1 IPOLXDNCMOVXCP-YZVVJARPSA-N 0.000 description 1
- IPOLXDNCMOVXCP-UHFFFAOYSA-N Lyciumin A Chemical compound C12=CC=CC=C2N2C=C1CC(C(O)=O)NC(=O)C(CO)NC(=O)CNC(=O)C(C(C)C)NC(=O)C2NC(=O)C(NC(=O)C1N(CCC1)C(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 IPOLXDNCMOVXCP-UHFFFAOYSA-N 0.000 description 1
- BARYJIKIMHXXOI-UHFFFAOYSA-N Lyciumin A methylate Natural products O=C1NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(C(=O)OC)CC(C2=CC=CC=C22)=CN2C1NC(=O)C(NC(=O)C1N(CCC1)C(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BARYJIKIMHXXOI-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- NNGFUSPIRIORIH-UHFFFAOYSA-H [Cr+3].[Cr+3].[O-]C(=O)c1ccccn1.[O-]C(=O)c1ccccn1.[O-]C(=O)c1ccccn1.[O-]C(=O)c1ccccn1.[O-]C(=O)c1ccccn1.[O-]C(=O)c1ccccn1 Chemical compound [Cr+3].[Cr+3].[O-]C(=O)c1ccccn1.[O-]C(=O)c1ccccn1.[O-]C(=O)c1ccccn1.[O-]C(=O)c1ccccn1.[O-]C(=O)c1ccccn1.[O-]C(=O)c1ccccn1 NNGFUSPIRIORIH-UHFFFAOYSA-H 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- QOWZHEWZFLTYQP-UHFFFAOYSA-K chromium(3+);triformate Chemical compound [Cr+3].[O-]C=O.[O-]C=O.[O-]C=O QOWZHEWZFLTYQP-UHFFFAOYSA-K 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000009923 sugaring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of auxiliary hyperglycemic compositions, include the component of following parts by weight：0.15~0.25 part of 45~55 parts of Astragalus Root P.E, 35~45 parts of Cortex Lycii extract, 25~35 parts of yam extract, 20~30 parts of kudzu root extract, 10~15 parts of Notogineng Extract, 9~12 parts of duck wheat and chromium picolinate.The present invention is using Astragalus Root P.E, Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract, duck wheat, chromium picolinate as primary raw material, by nourishing Yin and clearing heat, strengthening spleen, tonifying kidney, supplementing qi and nourishing yin, performance promoting blood circulation and removing blood stasis to the integrally-regulated of body, improve patient's glycometabolism and Anomalous lipid metablism, and beta Cell of islet regeneration and functional rehabilitation can be promoted, prevent diabetes and its complication；The formula compatibility reasonable science of the present invention has synergistic effect between each component, the health-care efficacy with auxiliary hyperglycemic, and without any side effects to body.
Description
Technical field
The present invention relates to health product technology field, it is related to the health products with effect of lowering blood sugar, is more particularly to a kind of auxiliary
Help hypoglycemic composition and preparation method thereof.
Background technology
Diabetes are to be only second to the third-largest disease of cardiovascular and cerebrovascular disease and tumour in the world at present, and hyperglycemia is that it is main
Clinical symptoms.With the development of the society, the accelerating rhythm of life, the variation of environment and the pressure of various aspects are increasing, entirely
Ball diabetic just steeply rises with surprising rapidity, continuously takes that oral hypoglycemic agents will appear drug failure, insulin supports
The problems such as anti-and hyperinsulinemia, seriously affect people’s lives quality and health.Traditional Chinese medicine prevention diabetes history
Long, lot of experiments in recent years proves, active ingredient of Chinese herbs alkaloid, flavones, saponin(e, polysaccharide, terpene, how unsaturated
Aliphatic acid etc. all has the function of preventing diabetes, and lasting medicine, Small side effects.
Currently, the hypoglycemic main function mechanism of Western medicine is to promote insulin secretion, the level for reducing glucagon, suppression
Sugaring heteroplasia adjusts glycometabolism and improves insulin resistance, but Western medicine efficacy time is of short duration and side effect is big, some Western medicine exist
There are the high risk of hypoglycemia, long-time service that can cause complication in treatment.And Diabetes Mellitus Treated With Traditional Chinese Medicine has multipath, more targets
The pharmacology of point, polytropism.Diabetes Mellitus Treated With Traditional Chinese Medicine is with nourishing Yin and clearing heat, kidney and spleen invigorating, supplementing qi and nourishing yin, promoting blood circulation and removing blood stasis for base
This principle, it is advantageous that blood glucose can not only be reduced, moreover it is possible to play the feature integrally-regulated to body, be improved by dialectical implementation
Patient's glycometabolism and Anomalous lipid metablism, and beta Cell of islet regeneration and functional rehabilitation can be promoted, diabetes and its complication are prevented,
Being compared with Western medicine has irreplaceable advantage and potentiality.
It is found by retrieving state food pharmaceuticals administration general bureau (CFDA) database, is eaten in the health care of national approved
In product, the health food with auxiliary hyperglycemic function only 20 or so.And some of which product is due to various reasons not
Listing has been quit listing, and practical product quantity on sale is even more very few.Therefore, face huge diabetic population, exploitation with
Chinese medicinal material extract is very urgent to fill up gaps in market for health food of the primary raw material with auxiliary hyperglycemic.
Invention content
For overcome the deficiencies in the prior art, the purpose of the present invention is to provide a kind of auxiliary hyperglycemic composition and its systems
Preparation Method, using Chinese medical extract as primary raw material, edible safety has no toxic side effect guarantor's auxiliary hyperglycemic composition, and effect is aobvious
It writes；And the preparation method of the auxiliary hyperglycemic composition is simple, production cost is low, has good market development prospect.
The technical solution adopted by the present invention is：A kind of auxiliary hyperglycemic composition, the auxiliary hyperglycemic composition include
The component of following parts by weight：45~55 parts of Astragalus Root P.E, 35~45 parts of Cortex Lycii extract, 25~35 parts of yam extract,
0.15~0.25 part of 20~30 parts of kudzu root extract, 10~15 parts of Notogineng Extract, 9~12 parts of duck wheat and chromium picolinate.
Preferably, the auxiliary hyperglycemic composition includes the component of following parts by weight：48~52 parts of Astragalus Root P.E,
38~45 parts of bone bark extract, 30~32 parts of yam extract, 22~28 parts of kudzu root extract, 10~13 parts of Notogineng Extract,
0.2~0.25 part of 10~12 parts of duck wheat and chromium picolinate.
Preferably, the auxiliary hyperglycemic composition includes the component of following parts by weight：50 parts of Astragalus Root P.E, bone
40 parts of bark extract, 30 parts of yam extract, 25 parts of kudzu root extract, 12 parts of Notogineng Extract, 11 parts of duck wheat and pyridine first
0.20 part of sour chromium.
Radix Astragali has invigorating qi for strengthening superficies, the effect of diuretic and maintain drug, containing a large amount of abundant nutriments, and such as saponin(e, flavones, more
Sugared and needed by human amino acid etc..Radix Astragali has reduction blood viscosity, reduces thrombosis, reduce blood pressure, protect the heart
Dirty, bidirectional modulation blood glucose, Green Tea Extract damage, anti-aging, anti anoxia, antitumor, enhancing immunity of organism force effect, can be used to control
Treat the diseases such as heart disease, hypertension, diabetes.
The root bark of Chinese wolf-berry contains cinnamic acid (Cinnamic acid) and volume aldehydes matter, glycine betaine (Betaine), still detaches
Obtain Ke's alkali A (Kukoamine, Kukoamine A), matrimony vine element A (Lyciumin A), matrimony vine element B (Lyciumin B), β-paddy
Sterol (β-Sitosterol), linoleic acid (Linoleic acid), leukotrienes (Linolenic acid), 1 acid etc., ground bone
Skin has apparent leveling to hyperglycemia, and hypoglycemia will not occur, and is hypoglycemic good medicine.
Chinese yam can tonifying Qi and yin-nourishing, mend without stagnant, foster and oiliness, enriching spleen-QI and beneficial stomach-Yin are wanted for flat tonifying spleen and stomach
Medicine is suitable for diabetic and is eaten for a long time, has significant curative effect to levis diabetes.
Pueraria lobata is cool in nature, gas is flat, sweet in flavor, and tool heat-clearing, fall fire, all effects of toxin expelling, modern medicine study show：It is different in pueraria lobata
Flavone compound Puerarin has certain curative effect to hypertension, hyperlipidemia, hyperglycemia and cardiovascular and cerebrovascular disease.
Radix Notoginseng is just acknowledged as promoting blood circulation and removing blood stasis, the detumescence ding-tong that have effects that significant since ancient times, have " invaluable ",
The good reputation of " southern part of the country god grass ", possesses thousands of years of medicinal history, has very high medical value, and modern pharmacological research confirms, and three
Seven pairs of glycometabolisms have dual regulation.Notoginsenoside C1 can reduce alloxan diabetes mouse blood sugar, and effect is closed in dose-effect
System, and the blood glucose increasing effect of energy antagonism glucagon, and PNS then has the blood glucose increasing effect of collaboration glucagon.
Duck wheat is medicine-food two-purpose crop very few in nature, and bitter buckwheat -- seven major nutrient rolls into one completely, is not
Medicine is not health products, is that can work as the food that meal is eaten, because of its special growing environment, bitter buckwheat itself is just rich in selenium, can be right
Human body plays the role of nature Selenium Supplement, there is remarkable healthy nutritive value and outstanding dietotherapy effect, be known as " five cereals it
King ", three drop food (blood pressure lowering, hypoglycemic, reducing blood lipid), according to《Compendium of Materia Medica》Record " buckwheat is bitter in taste, it is cold, have benefiting energy,
Continuous spirit, sharp knowledge, the wide intestines stomach invigorating of sending down abnormally ascending effect ", long-term drinking can improve physical condition, reduce hyperglycemia, hypertension,
The incidence of hyperlipidemia can effectively prevent diabetes, and have certain antitumaous effect, be the ideal health care food of the middle-aged and the old
Product.
Chromium picolinate is that a kind of supplement for diabetes B or selective drug, experimental evidence are shown, pyridine first
Sour chromium has an impact in terms of absorbing glucose by p38MAPK activations, and chromium is believed to enhancing insulin function, causes
Insulin sensitivity enhances in diabetes B.
In summary raw material can be seen that Astragalus Root P.E, Cortex Lycii extract, yam extract, kudzu root extract, three
Seven extracts, duck wheat extract, chromium picolinate are reasonable according to monarch compatibility, and synergistic effect has good auxiliary
Function of blood sugar reduction.
Preferably, Astragaloside content >=0.2wt% contained in Astragalus Root P.E, pueraria lobata contained in kudzu root extract
Cellulose content >=15wt%, contained Total saponin (in terms of sanchinoside E1, Rg1, Rg2) >=75wt% in Notogineng Extract, pyridine first
Sour chromium purity >=98%.
Preferably, in the auxiliary hyperglycemic composition being prepared, Astragaloside content >=0.04wt%, chromium picolinate
Content be not less than 10mg/100g.
Preferably, the Astragalus Root P.E is prepared as follows to obtain：Dry astragalus root raw material is taken, is cleaned, is done
It is dry, it crushes, is added 8-12 times and measures water, ebuillition of heated extracts 3-4 times, 2-3 hours each, merges extracting solution, in temperature 60~70
DEG C, the medicinal extract of proportion d=1.20 is concentrated under reduced pressure under conditions of 0.06~0.08MPa of vacuum degree, standing cools, and second is added in medicinal extract
Alcohol stirs, and staticly settles, centrifugal sediment, and sediment continuously adds ethyl alcohol stirring, stands centrifugation, puts the precipitate in temperature 60
~70 DEG C, be dried under reduced pressure under the conditions of 0.06~0.08MPa of vacuum degree, crush, cross 80 mesh sieve, the dry powder collected is Radix Astragali
Extract.
Preferably, the Cortex Lycii extract is prepared as follows to obtain：The root bark of Chinese wolf-berry is crushed, is measured with 5-8 times
66-72% alcohol refluxs extract 3-4 times, extract 1-3h, merging filtrate every time；Filtrate is placed in 60~70 DEG C of temperature, vacuum
It is concentrated under reduced pressure into relative density 1.15~1.25 under the conditions of 0.06~0.08MPa of degree, ethyl alcohol is recycled, obtains thick medicinal extract；By thick leaching
Cream adds limewash stirring, gained alkaline solution to be neutralized with formic acid, adds the 8-12 times of ethyl alcohol recrystallization measured, and filters, in vacuum degree
It is dried under reduced pressure, crushes under conditions of 0.06~0.08MPa, cross 80 mesh sieve, the dry powder collected is Cortex Lycii extract.
Preferably, the yam extract is prepared as follows to obtain：Chinese yam is cleaned into drying, is broken into thick
Grain is extracted 2-3 times with the 8-12 times of 66-72% alcohol reflux measured, and each extraction time is 1-3h, and filtering, merging filtrate obtains
Chinese yam extract；Chinese yam extract is placed under 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree be concentrated under reduced pressure into it is relatively close
Degree 1.15~1.25 recycles ethyl alcohol, obtains thick medicinal extract；Thick medicinal extract is placed in 60~70 DEG C of temperature, vacuum degree 0.06~0.08MPa items
It is dried under reduced pressure under part, obtains dry extract：By gained dry extract through crushing, 80 mesh sieve is crossed, the dry powder collected is Chinese yam extraction
Object.
Preferably, the kudzu root extract is prepared as follows to obtain：Pueraria lobata is cleaned into drying, is broken into thick
Grain, with 8-12 times of water refluxing extraction measured 2-3 time, each extraction time is 1-3h, filtering, merging filtrate, obtains Chinese yam and extracts
Liquid；Chinese yam extract is placed under 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree be concentrated under reduced pressure into relative density 1.10~
1.15, obtain thick medicinal extract；Thick medicinal extract is spray-dried, the inlet temperature of spray drying is 180 ± 5 DEG C, and outlet temperature is 70 ± 5
DEG C, obtain dry extract；By gained dry extract through crushing, 80 mesh sieve is crossed, the dry powder collected is kudzu root extract.
Preferably, the Notogineng Extract is prepared as follows to obtain：Radix Notoginseng is cleaned into drying, is broken into thick
Grain is extracted 2-3 times with the 8-12 times of 66-72% alcohol reflux measured, and each extraction time is 1-3h, and filtering, merging filtrate obtains
Radix Notoginseng extracting solution；Radix Notoginseng extracting solution is placed under 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree be concentrated under reduced pressure into it is relatively close
Degree 1.15~1.25 recycles ethyl alcohol, obtains thick medicinal extract；Thick medicinal extract is placed in 60~70 DEG C of temperature, vacuum degree 0.06~0.08MPa items
It is dried under reduced pressure under part, obtains dry extract：Gained dry extract crosses 80 mesh sieve, the dry powder collected is Notogineng Extract through crushing.
The present invention also provides the preparation methods of auxiliary hyperglycemic composition, include the following steps：
1) it crushes, be sieved：The duck wheat of recipe quantity, Astragalus Root P.E, Cortex Lycii extract, Chinese yam extraction are weighed respectively
Then object, kudzu root extract, Notogineng Extract, chromium picolinate are crushed and are sieved for subsequent use respectively；
2) chromium picolinate after sieving is pressed into the first duck wheat mixing with 1/7-1/6 of equal increments method, then is carried with Radix Astragali
Take object, Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract, remaining duck wheat to be mixed together to get
To auxiliary hyperglycemic composition.
Preferably, duck wheat is crushed, is sieved with 100 mesh sieve；Astragalus Root P.E, Cortex Lycii extract, yam extract, pueraria lobata
Extract, Notogineng Extract and chromium picolinate crush, and then cross 80 mesh sieve respectively.
Preferably, step 1) and 2) at 300,000 grades produce clean area conditions above under operate.
Preferably, since chromium picolinate dosage is seldom, it is difficult to the mixing directly together with all raw materials, so to use etc.
Incremental method is measured, first by it and 1/7-1/6 duck wheats (such as 1.5 portions of duck wheats) mixing, then is mixed together with other raw materials.
The present invention also provides a kind of medicaments of auxiliary hyperglycemic, by weight percentage, the medicine of the auxiliary hyperglycemic
Agent includes the auxiliary hyperglycemic composition described in 90-99.5%, the dosage form of the medicament of the auxiliary hyperglycemic be tablet, pill,
Powder or capsule.It is furthermore preferred that the dosage form of the medicament of the auxiliary hyperglycemic is capsule.
Due to containing duck wheat, Astragalus Root P.E, Notogineng Extract, kudzu root extract etc. in the formula of the present composition
The partially bitter Chinese medical extract of some tastes, it is not so good to make powder, tablet taste, although and adding essence and sweetener can increase
Flavoring taste and sweet taste, but compatible change may be will produce, effect is influenced, so the composition of the present invention is most suitable for making capsule,
This can not only cover bad smell and bitter taste, but also convenient for metering and take, easy to carry.
It is furthermore preferred that the medicament of the auxiliary hyperglycemic includes the auxiliary hyperglycemic composition described in 95-99.5%
Ethyl alcohol percentage composition in the present invention is weight percentage, such as " 68-72% ethyl alcohol ", refers to every 100g second
Contain ethyl alcohol 68-72g in alcohol solution." relative density " in the present invention each means the density relative to water at 60 DEG C.
The beneficial effects of the invention are as follows：
(1) present invention with Astragalus Root P.E, Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract,
Duck wheat, chromium picolinate are primary raw material, by nourishing Yin and clearing heat, strengthening spleen, tonifying kidney, supplementing qi and nourishing yin, performance promoting blood circulation and removing blood stasis to body
It is integrally-regulated, improve patient's glycometabolism and Anomalous lipid metablism, and beta Cell of islet can be promoted to regenerate and functional rehabilitation, prevention sugar
Urine disease and its complication；
(2) formula compatibility reasonable science of the invention has synergistic effect between each component, has significant health care work(
Effect；
(3) product that the present invention is produced, proves through animal function test and toxicological test, the guarantor with auxiliary hyperglycemic
Strong effect, and it is without any side effects to body, it can trust long-term consumption；
(4) product of the invention is produced and processed with the preparation technique of modernization, and production technology level is advanced, and is operated
Conveniently, it can be achieved that industrialization continuous production, production cost are relatively low.
Specific implementation mode
Invention is further described in detail With reference to embodiment.
A kind of auxiliary hyperglycemic composition, includes the component of following parts by weight：45~55 parts of Astragalus Root P.E, the root bark of Chinese wolf-berry carry
Take 35~45 parts of object, 25~35 parts of yam extract, 20~30 parts of kudzu root extract, 10~15 parts of Notogineng Extract, duck wheat 9
~12 parts and 0.15~0.25 part of chromium picolinate.
It is furthermore preferred that the auxiliary hyperglycemic composition includes the component of following parts by weight：50 parts of Astragalus Root P.E,
40 parts of bone bark extract, 30 parts of yam extract, 25 parts of kudzu root extract, 12 parts of Notogineng Extract, 11 parts of duck wheat and pyridine
0.20 part of chromic formate.
Preferably, Astragaloside content >=0.2wt% contained in Astragalus Root P.E, pueraria lobata contained in kudzu root extract
Cellulose content >=15wt%, contained Total saponin (in terms of sanchinoside E1, Rg1, Rg2) >=75wt% in Notogineng Extract, pyridine first
Sour chromium chromium picolinate purity >=98%.
Preferably, Astragalus Root P.E is prepared as follows to obtain：Dry astragalus root raw material is taken, is cleaned, dry, powder
Broken, 10 times of amount water, ebuillition of heated extracts three times, 2 hours every time, merges extracting solution three times, in 60~70 DEG C of temperature, vacuum degree
The medicinal extract of proportion d=1.20 is concentrated under reduced pressure under conditions of 0.06~0.08MPa, standing cools, and ethyl alcohol stirring is added in medicinal extract, quiet
Set precipitation, centrifugal sediment, sediment continuously adds ethyl alcohol stirring, stands centrifugation, puts the precipitate in 60~70 DEG C of temperature, true
It is dried under reduced pressure, crushes under the conditions of 0.06~0.08MPa of reciprocal of duty cycle, cross 80 mesh sieve, the dry powder collected i.e. Astragalus Root P.E.
Cortex Lycii extract is prepared as follows to obtain：The root bark of Chinese wolf-berry is crushed, 70% alcohol reflux measured with 6 times
Extraction 3 times, extracts 1.5h, merging filtrate every time；Filtrate is placed in 60~70 DEG C of temperature, vacuum degree 0.06~0.08MPa conditions
Under be concentrated under reduced pressure into relative density 1.15~1.25, recycle ethyl alcohol, obtain thick medicinal extract；By thick medicinal extract plus limewash stirring, gained
Alkaline solution formic acid neutralizes, and adds the ethyl alcohol recrystallization of 10 times of amounts, filters, and is depressurized under conditions of 0.06~0.08MPa of vacuum degree
It dry, pulverize, cross 80 mesh sieve, the dry powder collected i.e. Cortex Lycii extract.
Yam extract is prepared as follows to obtain：Chinese yam is cleaned into drying, is broken into coarse granule, is measured with 10 times
70% alcohol reflux extract 2 times, each extraction time is 1.5h, and filtering, merging filtrate obtains Chinese yam extract；By Chinese yam
Extracting solution is placed in 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree is concentrated under reduced pressure into relative density 1.15~1.25, recycles second
Alcohol obtains thick medicinal extract；Thick medicinal extract is placed under the conditions of 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree and is dried under reduced pressure, dry leaching is obtained
Cream：Gained dry extract crosses 80 mesh sieve, the dry powder collected i.e. yam extract through crushing.
Kudzu root extract is prepared as follows to obtain：Pueraria lobata is cleaned into drying, is broken into coarse granule, is measured with 10 times
Water refluxing extraction 2 times, each extraction time is 1.5h, and filtering, merging filtrate obtains Chinese yam extract；By Chinese yam extract
Be placed in 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree is concentrated under reduced pressure into relative density 1.10~1.15, obtain thick medicinal extract；It will
Thick medicinal extract is spray-dried (180 ± 5 DEG C of inlet temperature, 70 ± 5 DEG C of outlet temperature), obtains dry extract：Gained dry extract is through crushing, mistake
80 mesh sieve, the dry powder collected i.e. kudzu root extract.
Notogineng Extract is prepared as follows to obtain：Radix Notoginseng is cleaned into drying, is broken into coarse granule, is measured with 10 times
70% alcohol reflux extract 2 times, each extraction time is 1.5h, and filtering, merging filtrate obtains Radix Notoginseng extracting solution；By Radix Notoginseng
Extracting solution is placed in 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree is concentrated under reduced pressure into relative density 1.15~1.25, recycles second
Alcohol obtains thick medicinal extract；Thick medicinal extract is placed under the conditions of 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree and is dried under reduced pressure, dry leaching is obtained
Cream：Gained dry extract crosses 80 mesh sieve, the dry powder collected i.e. Notogineng Extract through crushing.
The present invention also provides the preparation methods of auxiliary hyperglycemic composition, include the following steps：
1) it crushes, be sieved：The duck wheat of recipe quantity, Astragalus Root P.E, Cortex Lycii extract, Chinese yam extraction are weighed respectively
Then object, kudzu root extract, Notogineng Extract and chromium picolinate are crushed and are sieved for subsequent use respectively；
2) chromium picolinate after sieving is pressed into the first duck wheat mixing with 1/7-1/6 of equal increments method, then is carried with Radix Astragali
Take object, Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract, remaining duck wheat to be mixed together to get
To auxiliary hyperglycemic composition.
Preferably, duck wheat is crushed, is sieved with 100 mesh sieve；Astragalus Root P.E, Cortex Lycii extract, yam extract, pueraria lobata
Extract, Notogineng Extract and chromium picolinate crush, and then cross 80 mesh sieve respectively.
Preferably, step 1) and 2) at 300,000 grades produce clean area conditions above under operate.
The present invention also provides a kind of medicaments of auxiliary hyperglycemic, by weight percentage, the medicine of the auxiliary hyperglycemic
Agent includes the auxiliary hyperglycemic composition described in 90-99%, and the dosage form of the medicament of the auxiliary hyperglycemic is tablet, pill, dissipates
Agent or capsule.
Embodiment 1
A kind of auxiliary hyperglycemic capsule, including following component by weight：50 parts of Astragalus Root P.E, root bark of Chinese wolf-berry extraction
40 parts of object, 30 parts of yam extract, 25 parts of kudzu root extract, 12 parts of Notogineng Extract, 11 parts of duck wheat, chromium picolinate 0.20
Part and dextrin 1.5 parts (auxiliary materials).
The preparation method of auxiliary hyperglycemic capsule as described above includes the following steps：
A, crushing, sieving：Recipe quantity duck wheat is crushed, is sieved with 100 mesh sieve；Weigh respectively recipe quantity Astragalus Root P.E,
Then Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract, chromium picolinate, dextrin cross 80 mesh respectively
Sieve, it is spare；
B, it mixes：The chromium picolinate after sieving is uniformly mixed with dextrin first, then is extracted with Astragalus Root P.E, the root bark of Chinese wolf-berry
Object, yam extract, kudzu root extract, Notogineng Extract, duck wheat are placed in mixing machine and mix 25~35min together, until color and luster
Uniformity, no color differnece obtain and always mix powder；
C, filling, polishing, packaging：Total mixed powder is filled with capsule filling machine, by 0.4g/ specification loading amounts, just
Minus deviation 9%, obtains health-caring capsule, and polishing, packaging are put in storage after the assay was approved.
Wherein, the above operation is carried out under 300,000 grades of production clean area conditions above for meeting GB17405 requirements.
Embodiment 2
A kind of auxiliary hyperglycemic capsule, including following component by weight：45 parts of Astragalus Root P.E, root bark of Chinese wolf-berry extraction
42 parts of object, 33 parts of yam extract, 26 parts of kudzu root extract, 11 parts of Notogineng Extract, 9 parts of duck wheat, chromium picolinate 0.15
Part and dextrin 1.55 parts (auxiliary materials).
The preparation method of auxiliary hyperglycemic capsule as described above includes the following steps：
A, crushing, sieving：Recipe quantity duck wheat is crushed, is sieved with 100 mesh sieve；Weigh respectively recipe quantity Astragalus Root P.E,
Then Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract, chromium picolinate, dextrin cross 80 mesh respectively
Sieve, it is spare；
B, it mixes：The chromium picolinate after sieving is uniformly mixed with dextrin first, then is extracted with Astragalus Root P.E, the root bark of Chinese wolf-berry
Object, yam extract, kudzu root extract, Notogineng Extract, duck wheat are placed in mixing machine and mix 25~35min together, until color and luster
Uniformity, no color differnece obtain and always mix powder；
C, filling, polishing, packaging：Total mixed powder is filled with capsule filling machine, by 0.4g/ specification loading amounts, just
Minus deviation 9%, obtains health-caring capsule, and polishing, packaging are put in storage after the assay was approved.
Wherein, the above operation is carried out under 300,000 grades of production clean area conditions above for meeting GB17405 requirements.
Embodiment 3
A kind of auxiliary hyperglycemic capsule, including following component by weight：55 parts of Astragalus Root P.E, root bark of Chinese wolf-berry extraction
37 parts of object, 28 parts of yam extract, 23 parts of kudzu root extract, 13 parts of Notogineng Extract, 12 parts of duck wheat, chromium picolinate 0.25
Part and dextrin 1.45 parts (auxiliary materials).
The preparation method of auxiliary hyperglycemic capsule as described above includes the following steps：
A, crushing, sieving：Recipe quantity duck wheat is crushed, is sieved with 100 mesh sieve；Weigh respectively recipe quantity Astragalus Root P.E,
Then Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract, chromium picolinate, dextrin cross 80 mesh respectively
Sieve, it is spare；
B, it mixes：The chromium picolinate after sieving is uniformly mixed with dextrin first, then is extracted with Astragalus Root P.E, the root bark of Chinese wolf-berry
Object, yam extract, kudzu root extract, Notogineng Extract, duck wheat are placed in mixing machine and mix 25~35min together, until color and luster
Uniformity, no color differnece obtain and always mix powder；
C, filling, polishing, packaging：Total mixed powder is filled with capsule filling machine, by 0.4g/ specification loading amounts, just
Minus deviation 9%, obtains health-caring capsule, and polishing, packaging are put in storage after the assay was approved.
Wherein, the above operation is carried out under 300,000 grades of production clean area conditions above for meeting GB17405 requirements.
Embodiment 4
A kind of auxiliary hyperglycemic pill, including following component by weight：50 parts of Astragalus Root P.E, root bark of Chinese wolf-berry extraction
40 parts of object, 30 parts of yam extract, 25 parts of kudzu root extract, 12 parts of Notogineng Extract, 11 parts of duck wheat, chromium picolinate 0.20
Part.
The preparation method of the auxiliary hyperglycemic water-bindered pill as described above includes the following steps：
A, crushing, sieving：Recipe quantity duck wheat is crushed, is sieved with 100 mesh sieve；Weigh respectively recipe quantity Astragalus Root P.E,
Then Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract, chromium picolinate, dextrin cross 80 mesh respectively
Sieve, it is spare；
B, it mixes：First the chromium picolinate after sieving is uniformly mixed according to equal increments method with 1.5 portions of duck wheats, then with
Astragalus Root P.E, Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract, remaining duck wheat are placed in together
Mixing machine mixes 25~35min, until uniform color is consistent, no color differnece, obtains and always mixes powder；
C, molding：Will always mixed powder is dispensed in coating pan in right amount, water be sprayed under coating pan rotation, make medicinal powder all at
The little particle of moistening adds a small amount of fine powder, continues to roll certain time, keeps little particle solid, micro- close, then dusting of spraying water, such as
Operation is repeated in this, rule ball mould, be further continued for being molded after screening.
D, molding is increased：After mould is made, alternately water is added to add powder under coating pan rotation, constantly rotated, until pellet
It is gradually increased molding, makes that 0.4g/ (positive and negative deviations 9%) smooth, spheroidal pellet, until meeting the requirements.
E, capping：Dispensed with appropriate always mixed powder, quickly turn over, rub, roll after close.
F, drying：The good pill of capping is taken out rapidly, is placed in 55 ± 5 DEG C of dryings to water content ＜ 9%.
G, ball is selected：Pellet is screened into uniform pellet with the medicine of 18 mesh sieve, too small pellet is general big again, and excessive is abnormal
Proper treatment is made in should separating for shape.
F, packaging and storage：Manufactured pill is wrapped up with paraffin paper, wax shell sealing indicates the name of an article, lot number, specification, examines
Warehousing after passing is stored at shady and cool drying.
Wherein, the above operation is carried out under 300,000 grades of production clean area conditions above for meeting GB17405 requirements.
Embodiment 5
A kind of auxiliary hyperglycemic powder, including following component by weight：50 parts of Astragalus Root P.E, root bark of Chinese wolf-berry extraction
40 parts of object, 30 parts of yam extract, 25 parts of kudzu root extract, 12 parts of Notogineng Extract, 11 parts of duck wheat, chromium picolinate 0.20
Part.
The preparation method of auxiliary hyperglycemic powder as described above includes the following steps：
1) it crushes, be sieved：Recipe quantity duck wheat is crushed, is sieved with 100 mesh sieve；Duck wheat, the Radix Astragali of recipe quantity are weighed respectively
Extract, Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract and chromium picolinate, then crush respectively
And 80 mesh sieve is crossed, it is spare；
2) it mixes：Chromium picolinate after sieving is pressed into equal increments method elder generation and 1.5 parts of duck wheat mixings, then is carried with Radix Astragali
It takes object, Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract, remaining duck wheat to be mixed together, obtains
Always mixed powder.
3) it packs：To always mix powder powder automatic dose dividing apparatus and powder quantitative package machine (press 0.4g/ bags of specification loading amount,
Positive and negative deviation 9%) weight packaging is carried out, hypoglycemic powder is obtained, is put in storage after the assay was approved.
Wherein, the above operation is carried out under 300,000 grades of production clean area conditions above for meeting GB17405 requirements.
Auxiliary hyperglycemic pill and embodiment 5 prepared by auxiliary hyperglycemic capsule prepared by embodiment 1-3, embodiment 4
The auxiliary hyperglycemic powder of preparation is tested.
One, the auxiliary hyperglycemic pill and embodiment 5 of the auxiliary hyperglycemic capsule, the preparation of embodiment 4 that prepared by embodiment 1-3
The auxiliary hyperglycemic powder function of blood sugar reduction of preparation is tested
1. mouse experiment
1.1 experiment mice
Select SPF grades of male KM mouse (26 ± 2g)
1.2 material
1.2.1 reagent
Alloxan (Sigma Co., USA), One Touch Horizon whip survey type blood glucose monitoring system and blood sugar detection
Test paper (Johnson Co.), triglycerides, total cholesterol assay kit
1.2.2 sample
The auxiliary hyperglycemic pill and embodiment 5 of auxiliary hyperglycemic capsule, the preparation of embodiment 4 prepared by embodiment 1-3 are made
Standby auxiliary hyperglycemic powder.
1.2.3 instrument
Blood glucose meter, full automatic biochemical apparatus, visible spectrophotometer, microplate reader, balance.
1.3 dosage are grouped and given the test agent gives the time
Experiment sets three dosage groups and a model control group, and tested material dosage is respectively 0.4g/kg.bw, 0.8g/
Kg.bw and 1.2g/kg.bw (10,20 and 30 times that are respectively equivalent to human body recommended intake).Each dosage component also known as take 2g,
It is prepared by the auxiliary hyperglycemic pill and embodiment 5 of auxiliary hyperglycemic capsule, the preparation of embodiment 4 prepared by 4g and 6g embodiments 1-3
Auxiliary hyperglycemic powder, be dissolved in 100ml distilled water, by 20ml/kg.bw gavages, blank control group mouse gavage equivalent
Distilled water, once a day, continuous gavage carry out following experiment respectively after 30 days.
1.4 experimental method
1.4.1 reducing fasting blood-glucose experiment
1.4.1.1 intact animal empty stomach hypoglycemic is tested
Empirically the tail blood blood glucose value of preceding fasting 5h (free water) is divided into control group and test sample group [gives 1.2g/
Kg.bw tested materials], every group 10, compare fasting blood sugar after 2 groups of experiment 30d.
1.4.1.2 alloxan hyperglycemia model mouse empty stomach hypoglycemic is tested
1. 50 mouse fasting are for 24 hours, alloxan (45mg/kg iv) is given, fasting 5h measures tail blood blood glucose after 7d.
2. hypoglycemic is tested：Each 40 of tail blood blood glucose value hyperglycemia model animal within the scope of 10~25m mol/L is selected, by blood
Sugared value is divided into model control group and 3 dosage groups.Each group mouse blood sugar value and blood glucose decline percentage before and after comparative experiments.
1.4.2 alloxan hyperglycemia model animal carbohydrate tolerance test
Above-mentioned hypoglycemic off-test, each dosage group give various concentration given the test agent, and model control group gives same volume steaming
Distilled water, orally administration 2.0g/kg glucose solutions after 15min, take tail hematometry to 0 after glucose, the blood glucose value of 0.5,2h, see
Examine the variation of each group each time point Area under the curve of blood glucose after to glucose solution.
1.5 experimental data
The data surveyed are counted with variance analysis using SPSS10.0 softwares.
2. result
2.1 hypoglycemic medicaments increase weight to normal mouse and the influence of fasting blood-glucose
It is prepared by the auxiliary hyperglycemic capsule of orally administration normal mouse 1.2g/kg.bw embodiments 1-3 preparations, embodiment 4
Auxiliary hyperglycemic powder 30d prepared by auxiliary hyperglycemic pill and embodiment 5, test sample group (high dose) mouse increase weight and move
Compared with the control group, difference is not statistically significant (P ＞ 0.05) for object fasting blood sugar.It is shown in Table 1.
1 hypoglycemic medicament of table increases weight to normal mouse and the influence of fasting blood sugar
2.2 hypoglycemic medicaments are to the weightening of alloxan hyperglycemia model mouse, fasting blood sugar and fasting blood-glucose rate of descent
Influence
Auxiliary hyperglycemic glue prepared by the embodiment 1-3 of orally administration alloxan hyperglycemia model mouse various dose
Capsule, embodiment 4 prepare auxiliary hyperglycemic pill and embodiment 5 prepare auxiliary hyperglycemic powder 30d, each dosage group with compare
Group weightening is compared, no significant difference (P ＞ 0.05)；Each dosage group blood glucose value of fasting 5h fasting blood sugars is below control
Group, and high dose group is compared with the control group, difference is statistically significant；Each dosage group fasting blood-glucose rate of descent is above control group
And high, middle dose group is compared with the control group, difference statistically significant (P ＜ 0.05 or P ＜ 0.01) is shown in Table 2.Result above is said
The auxiliary hyperglycemic pill and embodiment 5 of auxiliary hyperglycemic capsule, the preparation of embodiment 4 prepared by bright embodiment 1-3 prepare auxiliary
It helps hypoglycemic powder to have reduction alloxan hyperglycemia model mouse fasting blood sugar and increases the effect of its fasting blood-glucose rate of descent.
2 hypoglycemic medicament of table increases weight to alloxan hyperglycemia model mouse and the influence of fasting blood-glucose
Note：Compared with alloxan hyperglycemia model control group, * P ＜ 0.05, * * P ＜ 0.01；Blood glucose declines percentage
Fasting blood sugar × 100% before (%)=(fasting blood sugar after fasting blood sugar-experiment before experiment)/experiment.
Influence of the 2.3 hypoglycemic medicaments to alloxan hyperglycemia model glucose tolerance in mice
It can see from table 3, in carbohydrate tolerance test, each dosage group mouse is below pair to glucose 0,0.5, the blood glucose value of 2h
According to group.Give the blood glucose value high dose group of 0.5h after glucose compared with the control group, P ＜ 0.05.To the blood of 0.5h after glucose
Sugar is worth high, middle dose group compared with the control group, P ＜ 0.01.Give the blood glucose value high dose group of 2h and control group ratio after glucose
Compared with P ＜ 0.01；Middle dose group compared with the control group, P ＜ 0.05；Low dose group each time point compared with the control group, the equal nothing of difference
Statistical significance (P ＞ 0.05).Each dosage group mouse is below control group to Area under the curve of blood glucose after glucose, and it is high, in
Compared with the control group, difference is statistically significant (P ＜ 0.05 or P ＜ 0.01) for dosage group.The experimental results showed that hypoglycemic medicament
Resistance to sugar amount test result it is positive.
The influence of the 3 resistance to sugar amount of compound for reducing blood suger alloxan blood glucose model mice of table
Note：Compared with alloxan hyperglycemia model control group, * P ＜ 0.05, * * P ＜ 0.01；Area under the curve of blood glucose=
0.25 × (0h blood glucose value+4 × 0.5h+3 × 2h of blood glucose value blood glucose values)
3 conclusions
Hypoglycemic medicament 0.4g/kg.bw, 0.8g/kg.bw and 1.2g/kg.bw the continuous gavage 30d of orally administration mouse,
1.2g/kg.bw groups are on normal mouse weight and fasting blood sugar without influence；There is raising empty alloxan hyperglycemia model mouse
Abdomen blood glucose rate of descent, reduce fasting blood sugar and reducing give 0 after glucose, 0.5, the effect of 2h Area under the curve of blood glucose；
0.8g/kg.bw dosage can increase alloxan hyperglycemia model mouse fasting blood-glucose rate of descent, reduction gives 0 after glucose,
0.5, the Area under the curve of blood glucose of 2h.Foundation《Health food is examined and assessment technique specification》Version in 2003, function of health food
Learn assessment process and method of inspection specification, three " the auxiliary hyperglycemic function method of inspection of second part function assessment evaluation test method
Criterion ", judge the sample have auxiliary hyperglycemic function.
Two, the auxiliary hyperglycemic composition Toxicological evaluation experiment that prepared by the present invention：
1, acute toxicity test (MTD methods)
SD rats (weight 180g-220g) 20, half male and half female.If a dosage groups of 15g/kg.bw-.It accurately weighs tested
Object 90g adds distilled water to be suspended to 240ml, divides 2 oral gavages, interval 4 small under animal fasting state by 2ml/100g.bw
When, dead animal number and general health situation in two weeks are observed after gavage, and the acute poison of tested material is judged according to maximal tolerance dose
Property.
4 are the results are shown in Table, after auxiliary hyperglycemic composition 15g/kg.bw dosage prepared by the present invention is orally contaminated, in two weeks
Animal dead is had no, also without apparent poisoning symptom or adverse reaction.I.e. this inspection product are to female, male SD rat acute oral
MTD is more than 15g/kg.bw, belongs to non-toxic type.
The acute oral toxicity test result of auxiliary hyperglycemic composition prepared by 4 present invention of table to SD rats
2,30 days feeding trials of rat
Ablactation SD rats are randomly divided into four groups by weight, every group 20, half male and half female.Experiment sets a control group (basis
Feed) and 1.2,2.8 and 4.0g/kg.bw, tri- tested material dosage groups (be respectively equivalent to 30,70 and of human body recommended intake
100 times).Feed formulation method：Auxiliary hyperglycemic composition prepared by 180g, 420g and 600g present invention is weighed, base is incorporated into
In plinth feed, 15kg feeds are made into, and are processed into pellet feeding animal.Animal freely ingests, continuous 30 days, observes mouse
Situation.
As a result：During control group and 3 dosage group animals were fed at 30 days, ingest, drink water, stool and urine it is normal, growth hair
It educates situation and general performance is good, do not observe evident act change and poisoning manifestations.
3, mouse inbred strain：
Male Kunming strain mice (weight 25g-35g) is randomly divided into 5 groups, every group 5.If negative control group (distilled water),
Positive controls (CP 40mg/kg.bw) and 2.5,5.0, tri- hypoglycemic composition dosage groups of 10.0g/kg.bw (each group distinguish
2.5,5.0 and 10.0g tested materials are weighed, respectively add distilled water to 20ml suspensions), by the oral gavage animals of 2ml/100g.bw, continuously
5 days.It puts to death animal within the 35th day after gavage for the first time, takes bilateral epididymal, by standardization program film-making, every animal observation 1000 is complete
Whole sperm records all kinds of defective sperm numbers.
The results are shown in Table 5, and the rate of teratosperm of positive controls is significantly higher than negative control group (P<0.01), auxiliary drop
The rate of teratosperm of each dosage group of blood glucose composition there are no significant compared with negative control group difference (P>0.05) this hair, is prompted
The auxiliary hyperglycemic composition of bright preparation is negative findings in mouse inbred strain.
The influence of auxiliary hyperglycemic composition prepared by 5 present invention of table to mouse Serum lactic acid content
Note：" 0 " is negative control；* *, P compared with negative control<0.01.
Conclusion：Auxiliary hyperglycemic composition prepared by the present invention is more than 15g/kg.bw to the acute oral MTD of rat, sentences
Belong to non-toxic type.Mouse inbred strain is negative findings.Animal health condition, life are had no in rat in feeding trial within 30 days
Change, the anomalous variations of hematological indices and organ-tissue form, auxiliary hyperglycemic composition of the invention is most according to a preliminary estimate accordingly
Big action-less dose is more than 4.0g/kg.bw (100 times of human body recommended intake).
Claims (10)
1. a kind of auxiliary hyperglycemic composition, which is characterized in that the auxiliary hyperglycemic composition includes the group of following parts by weight
Point：45~55 parts of Astragalus Root P.E, 35~45 parts of Cortex Lycii extract, 25~35 parts of yam extract, kudzu root extract 20~
0.15~0.25 part of 30 parts, 10~15 parts of Notogineng Extract, 9~12 parts of duck wheat and chromium picolinate.
2. auxiliary hyperglycemic composition according to claim 1, which is characterized in that the auxiliary hyperglycemic composition includes
The component of following parts by weight：50 parts of Astragalus Root P.E, 40 parts of Cortex Lycii extract, 30 parts of yam extract, kudzu root extract
0.20 part of 25 parts, 12 parts of Notogineng Extract, 11 parts of duck wheat and chromium picolinate.
3. auxiliary hyperglycemic composition according to claim 1 or 2, which is characterized in that yellow contained in Astragalus Root P.E
Stilbene glucoside content >=0.2wt%, puerarin content >=15wt% contained in kudzu root extract, contained total soap in Notogineng Extract
Glucoside (in terms of sanchinoside E1, Rg1, Rg2) >=75wt%, chromium picolinate purity >=98%.
4. auxiliary hyperglycemic composition according to claim 1 or 2, which is characterized in that the Astragalus Root P.E be by with
Lower section method is prepared：Dry astragalus root raw material is taken, cleans, dry, pulverize, 8-12 times is added and measures water, ebuillition of heated extraction
It is 3-4 times, 2-3 hours each, merge extracting solution, is depressurized under conditions of 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree dense
Be reduced to the medicinal extract of proportion d=1.20, standing cools, medicinal extract be added ethyl alcohol stirring, staticly settle, centrifugal sediment, sediment after
It is continuous that ethyl alcohol stirring is added, centrifugation is stood, puts the precipitate under the conditions of 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree and subtracts
Pressure dry, pulverize, and cross 80 mesh sieve, the dry powder collected is Astragalus Root P.E.
5. auxiliary hyperglycemic composition according to claim 1 or 2, which is characterized in that the Cortex Lycii extract be by
What following methods were prepared：The root bark of Chinese wolf-berry is crushed, is extracted 3-4 times with the 5-8 times of 66-72% alcohol reflux measured, is extracted every time
1-3h, merging filtrate；Filtrate is placed under the conditions of 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree and is concentrated under reduced pressure into relatively
Density 1.15~1.25 recycles ethyl alcohol, obtains thick medicinal extract；Thick medicinal extract plus limewash stirring, gained alkaline solution are neutralized with formic acid,
The 8-12 times of ethyl alcohol recrystallization measured is added, filters, is dried under reduced pressure under conditions of 0.06~0.08MPa of vacuum degree, is crushed, mistake
80 mesh sieve, and the dry powder collected is Cortex Lycii extract.
6. auxiliary hyperglycemic composition according to claim 1 or 2, which is characterized in that the yam extract be by with
Lower section method is prepared：Chinese yam is cleaned into drying, is broken into coarse granule, is extracted with the 8-12 times of 66-72% alcohol reflux measured
2-3 times, each extraction time is 1-3h, and filtering, merging filtrate obtains Chinese yam extract；Chinese yam extract is placed in temperature 60
~70 DEG C, relative density 1.15~1.25 is concentrated under reduced pressure under 0.06~0.08MPa of vacuum degree, recycle ethyl alcohol, obtain thick medicinal extract；It will
Thick medicinal extract is dried under reduced pressure under the conditions of being placed in 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree, obtains dry extract：By the dry leaching of gained
Cream crosses 80 mesh sieve, the dry powder collected is yam extract through crushing.
7. auxiliary hyperglycemic composition according to claim 1 or 2, which is characterized in that the kudzu root extract be by with
Lower section method is prepared：Pueraria lobata is cleaned into drying, is broken into coarse granule, with 8-12 times of water refluxing extraction measured 2-3 times, every time
Extraction time is 1-3h, and filtering, merging filtrate obtains Chinese yam extract；Chinese yam extract is placed in 60~70 DEG C of temperature, vacuum
It is concentrated under reduced pressure into relative density 1.10~1.15 under 0.06~0.08MPa of degree, obtains thick medicinal extract；Thick medicinal extract is spray-dried, is sprayed
Dry inlet temperature is 180 ± 5 DEG C, and outlet temperature is 70 ± 5 DEG C, obtains dry extract；By gained dry extract through crushing, 80 mesh are crossed
Sieve, the dry powder collected is kudzu root extract.
8. auxiliary hyperglycemic composition according to claim 1 or 2, which is characterized in that the Notogineng Extract be by with
Lower section method is prepared：Radix Notoginseng is cleaned into drying, is broken into coarse granule, is extracted with the 8-12 times of 66-72% alcohol reflux measured
2-3 times, each extraction time is 1-3h, and filtering, merging filtrate obtains Radix Notoginseng extracting solution；Radix Notoginseng extracting solution is placed in temperature 60
~70 DEG C, relative density 1.15~1.25 is concentrated under reduced pressure under 0.06~0.08MPa of vacuum degree, recycle ethyl alcohol, obtain thick medicinal extract；It will
Thick medicinal extract is dried under reduced pressure under the conditions of being placed in 60~70 DEG C of temperature, 0.06~0.08MPa of vacuum degree, obtains dry extract：Gained dry extract
Through crushing, 80 mesh sieve is crossed, the dry powder collected is Notogineng Extract.
9. the preparation method of the auxiliary hyperglycemic composition according to any one of claim 1-8, which is characterized in that including
Following steps：
1) it crushes, be sieved：The duck wheat of recipe quantity, Astragalus Root P.E, Cortex Lycii extract, yam extract, Pueraria lobota are weighed respectively
Then root extract, Notogineng Extract, chromium picolinate are crushed and are sieved for subsequent use respectively；
2) by the chromium picolinate after sieving by equal increments method first with the duck wheat mixing of 1/7-1/6, then with Astragalus Root P.E,
Cortex Lycii extract, yam extract, kudzu root extract, Notogineng Extract, remaining duck wheat are mixed together to get to auxiliary
Hypoglycemic composition.
10. a kind of medicament of auxiliary hyperglycemic, which is characterized in that by weight percentage, the medicament packet of the auxiliary hyperglycemic
The auxiliary hyperglycemic composition described in any one of claim 1-8 of 90-99.5% is included, the medicament of the auxiliary hyperglycemic
Dosage form is tablet, pill, powder or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810457024.8A CN108523129A (en) | 2018-05-14 | 2018-05-14 | A kind of auxiliary hyperglycemic composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810457024.8A CN108523129A (en) | 2018-05-14 | 2018-05-14 | A kind of auxiliary hyperglycemic composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108523129A true CN108523129A (en) | 2018-09-14 |
Family
ID=63477436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810457024.8A Pending CN108523129A (en) | 2018-05-14 | 2018-05-14 | A kind of auxiliary hyperglycemic composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108523129A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109007785A (en) * | 2018-09-26 | 2018-12-18 | 上饶市康可得生物科技有限公司 | A kind of auxiliary hyperglycemic blood fat reducing healthcare food |
| CN109430854A (en) * | 2018-09-18 | 2019-03-08 | 广东精核生物科技发展有限公司 | A kind of health care product and preparation method thereof |
| CN111544508A (en) * | 2020-03-23 | 2020-08-18 | 浙江金童生物科技有限公司 | Propolis, pseudo-ginseng and rehmannia pills capable of reducing blood sugar and preparation method of propolis, pseudo-ginseng and rehmannia pills |
| CN111603536A (en) * | 2020-06-12 | 2020-09-01 | 广西医科大学 | Oyster-carambola composite extract, tablet candy and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488202A (en) * | 2011-12-13 | 2012-06-13 | 北京阳光一佰生物技术开发有限公司 | Medicinal composition for treating diabetes and preparation method thereof |
| CN102743584A (en) * | 2012-06-21 | 2012-10-24 | 长春康彼达科技有限公司 | Traditional Chinese medicine for decreasing blood sugar and preparation method thereof |
| CN104644967A (en) * | 2015-02-15 | 2015-05-27 | 龚敏 | Pharmaceutical composition for treating I-type diabetes and application thereof |
| CN106176918A (en) * | 2015-04-29 | 2016-12-07 | 无限极（中国）有限公司 | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae |
| CN106262918A (en) * | 2016-10-14 | 2017-01-04 | 胡松茂 | A kind of diabetes vegetable food product formula |
-
2018
- 2018-05-14 CN CN201810457024.8A patent/CN108523129A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488202A (en) * | 2011-12-13 | 2012-06-13 | 北京阳光一佰生物技术开发有限公司 | Medicinal composition for treating diabetes and preparation method thereof |
| CN102743584A (en) * | 2012-06-21 | 2012-10-24 | 长春康彼达科技有限公司 | Traditional Chinese medicine for decreasing blood sugar and preparation method thereof |
| CN104644967A (en) * | 2015-02-15 | 2015-05-27 | 龚敏 | Pharmaceutical composition for treating I-type diabetes and application thereof |
| CN106176918A (en) * | 2015-04-29 | 2016-12-07 | 无限极（中国）有限公司 | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae |
| CN106262918A (en) * | 2016-10-14 | 2017-01-04 | 胡松茂 | A kind of diabetes vegetable food product formula |
Non-Patent Citations (2)
| Title |
|---|
| 宋建平: "三七根茎的化学成分研究", 《云南大学学报(自然科学版)》 * |
| 李春英等: "地骨皮中有效成分的提取及其降血糖调血脂作用研究", 《中国林副特产》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109430854A (en) * | 2018-09-18 | 2019-03-08 | 广东精核生物科技发展有限公司 | A kind of health care product and preparation method thereof |
| CN109430854B (en) * | 2018-09-18 | 2021-10-26 | 广东精核生物科技发展有限公司 | Health product and preparation method thereof |
| CN109007785A (en) * | 2018-09-26 | 2018-12-18 | 上饶市康可得生物科技有限公司 | A kind of auxiliary hyperglycemic blood fat reducing healthcare food |
| CN111544508A (en) * | 2020-03-23 | 2020-08-18 | 浙江金童生物科技有限公司 | Propolis, pseudo-ginseng and rehmannia pills capable of reducing blood sugar and preparation method of propolis, pseudo-ginseng and rehmannia pills |
| CN111603536A (en) * | 2020-06-12 | 2020-09-01 | 广西医科大学 | Oyster-carambola composite extract, tablet candy and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108523129A (en) | A kind of auxiliary hyperglycemic composition and preparation method thereof | |
| CN101152007B (en) | Health-care products composition and method for preparing the same | |
| CN106606529A (en) | Composition with auxiliary blood sugar reduction efficacy, and preparation method and application thereof | |
| CN102551065B (en) | Blood sugar reducing food series | |
| CN104784505B (en) | A kind of Dendrobium officinale health product of auxiliary hyperglycemic and preparation method thereof | |
| CN102836340A (en) | Pharmaceutical composition for benefiting vital energy, enriching blood and nourishing liver and kidney as well as preparation method and application thereof | |
| CN104107269A (en) | Functional blood sugar-reduction health product and preparation method thereof | |
| CN101019645B (en) | Health food for remitting fatigue and raising hypoxia tolerance and its preparation method | |
| CN103608024A (en) | Pharmaceutical composition for controlling blood sugar, blood lipid and body weight | |
| CN109045098A (en) | A kind of lower hyperlipidemia, hypertension, hyperglycemia lozenge and preparation method thereof | |
| CN103181560B (en) | Health food having effects of life cultivation and health preservation in winter and preparation method thereof | |
| CN102448479B (en) | A novel antidiabetic furostanolic saponin rich (fsr) fraction from fenugreek seeds | |
| CN106490611A (en) | A kind of Radix Notoginseng flower composition and its preparation method and application | |
| CN107801990A (en) | A kind of health food of auxiliary hyperglycemic and preparation method thereof | |
| CN115137770A (en) | Preparation method of traditional Chinese medicine product with efficacy of reducing blood fat and blood pressure | |
| CN106421741A (en) | Water-soluble olive leaf extract health-care product and preparation method thereof | |
| CN104127816B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN114145374A (en) | Astragalus membranaceus and corn stigma composite tea and preparation method and application thereof | |
| CN113995074A (en) | Molecular essence solid beverage with blood glucose reducing function and preparation method thereof | |
| WO2018072276A1 (en) | Health-care food and preparation method therefor | |
| CN107997170B (en) | Composition with blood fat reducing function and preparation method thereof | |
| CN106387915B (en) | Qi and coffee vigor-benefiting effervescent tablet and preparation process and application thereof | |
| CN106177416B (en) | A kind of traditional Chinese medicinal composition with effect of reducing blood sugar and preparation method thereof | |
| CN112544973B (en) | Auxiliary blood lipid-lowering composition, compound granule prepared from same, and preparation method and application of compound granule | |
| CN110973479A (en) | Low GI steamed bread and making method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |